Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer
C Pezaro, V Karavasilis, J De Bono - Annual review of medicine, 2013 - annualreviews.org
Suppression of gonadal androgens by medical or surgical castration remains the mainstay
of treatment for patients with advanced prostate cancer. However, the response to treatment …
of treatment for patients with advanced prostate cancer. However, the response to treatment …
Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer.
R Ferraldeschi, C Pezaro, V Karavasilis… - Annual Review of …, 2012 - europepmc.org
Suppression of gonadal androgens by medical or surgical castration remains the mainstay
of treatment for patients with advanced prostate cancer. However, the response to treatment …
of treatment for patients with advanced prostate cancer. However, the response to treatment …
Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer
R Ferraldeschi, C Pezaro… - Annual review of …, 2013 - pubmed.ncbi.nlm.nih.gov
Suppression of gonadal androgens by medical or surgical castration remains the mainstay
of treatment for patients with advanced prostate cancer. However, the response to treatment …
of treatment for patients with advanced prostate cancer. However, the response to treatment …